Vincerx Pharma, Inc. Retained Earnings
Vincerx Pharma, Inc. had Retained Earnings of -$194.19 million as of 2025-03-31, per its 10-Q filed 2025-05-15.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2025-05-15
- 2025-03-31: Retained Earnings (Accumulated Deficit) -$194.19M.
- 2024-12-31: Retained Earnings (Accumulated Deficit) -$189.19M.
- 2024-09-30: Retained Earnings (Accumulated Deficit) -$181.19M.
- 2024-06-30: Retained Earnings (Accumulated Deficit) -$173.35M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2025-03-31 | -$194.19M 10-Q · filed 2025-05-15 | |
| 2024-12-31 | -$189.19M 10-Q · filed 2025-05-15 | |
| 2024-09-30 | -$181.19M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | -$173.35M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | -$171.54M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | -$159.11M 10-K · filed 2025-03-27 | |
| 2023-09-30 | -$156.54M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | -$146.83M 10-Q · filed 2023-08-07 | |
| 2023-03-31 | -$135.68M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | -$118.95M 10-K · filed 2024-03-29 | -$121.34M 10-K · filed 2023-03-28 |
| 2022-09-30 | -$107.69M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | -$90.82M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | -$72.39M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | -$55.97M 10-K · filed 2023-03-28 | |
| 2021-09-30 | -$49.50M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | -$24.98M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | -$22.94M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | -$16.66M 10-K · filed 2022-03-29 | -$10.77M 10-K · filed 2021-03-22 |
| 2020-09-30 | -$555.30K 10-Q · filed 2020-11-10 | |
| 2020-06-30 | -$120.99K 10-Q · filed 2020-11-10 | |
| 2020-03-31 | -$13.45K 10-Q · filed 2020-05-06 | |
| 2019-12-31 | -$45.00K 10-K/A · filed 2021-05-14 | |
| 2019-06-30 | -$1.45K 10-K · filed 2020-09-23 |